Have Questions?
FILL OUT THE FORM BELOW
TO REQUEST YOUR CASE REVIEW
Latest Suboxone Tooth Decay Lawsuit Updates
Our attorneys are reviewing claims from patients who developed severe tooth decay, tooth loss, oral infections, or other dental injuries after long-term use of Suboxone sublingual film (buprenorphine/naloxone) prescribed for opioid use disorder treatment.
Claims are consolidated in MDL 3092, In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, in the U.S. District Court for the Northern District of Ohio before Judge Philip Calabrese.
To qualify, claimants generally need a documented Suboxone film prescription history of six months or longer, plus dental records showing tooth decay, cavities, tooth loss, or oral surgery that began or accelerated during film use.
Fill out the form to check your eligibility and find out if you qualify to file a claim.
The litigation alleges that Indivior Inc. (and predecessor Reckitt Benckiser) designed and marketed Suboxone sublingual film at a highly acidic pH that erodes tooth enamel during dissolution. Plaintiffs allege that the manufacturers knew about the dental risk for years but did not update the warning label until the FDA required it in June 2022, leaving prior patients exposed without adequate informed consent.
Dental injuries being investigated by Suboxone attorneys:
- Severe tooth decay (caries) at multiple sites simultaneously
- Enamel erosion and demineralization
- Tooth fractures (cracked, chipped, or broken teeth)
- Tooth loss requiring extraction
- Cavities at unusual locations (gum line, between teeth, cervical caries)
- Root canals and crown placement
- Dental implants and bridges
- Oral infections, abscesses, and gum disease
- Bone loss in the jaw (alveolar bone resorption)
- Dentures or full-mouth reconstruction
FDA Warning, June 2022: The FDA required Indivior to add a dental-decay warning to the Suboxone film label after reviewing 305 adverse-event reports from 2007 through mid-2021. Patients prescribed Suboxone before that label change did not receive the updated warning.
MDL 3092 Update: The Plaintiffs' Steering Committee is moving through discovery. Bellwether selection is in progress. The litigation centralized in the Northern District of Ohio (originally before Judge Polster, the longtime opioid MDL judge, with later reassignment) sits alongside a broader pattern of pharmaceutical injury claims our firm handles.
Table of Contents
[show]- What is Suboxone film and how it damages teeth
- The June 2022 FDA dental-decay warning
- Dental injuries linked to Suboxone film
- Named defendants: Indivior and Reckitt
- MDL 3092 status: court, judge, bellwether posture
- Who qualifies to file a Suboxone tooth decay lawsuit
- How to file and statute of limitations
The Suboxone Film Acidity Problem
(Sublingual Film Dental Injury Claims, May 2026)
Suboxone is a buprenorphine/naloxone combination prescribed for medication-assisted treatment (MAT, also called medications for opioid use disorder or MOUD) of opioid use disorder. Related buprenorphine products in the MAT space include Subutex (buprenorphine only), Zubsolv, Bunavail, and Sublocade (the long-acting injectable). The Suboxone sublingual film formulation dissolves under the tongue, where the buprenorphine is absorbed through the oral mucosa into the bloodstream. Office-based opioid treatment (OBOT) programs and outpatient addiction-medicine practices prescribe Suboxone film as a daily maintenance therapy.
The film's effectiveness depends on a low (acidic) pH that keeps the buprenorphine in solution and bioavailable. That same acidity bathes the teeth every time a patient takes a dose. For patients prescribed twice-daily or three-times-daily dosing over months and years, the cumulative acid exposure is substantial.
The plaintiffs' theory: long-term sublingual contact with an acidic pharmaceutical film erodes tooth enamel, demineralizes the dentin underneath, and triggers a pattern of rapid, widespread tooth decay that does not match the patient's pre-Suboxone dental history.
"My teeth were fine before Suboxone. Two years in, I needed seven extractions and full-mouth restoration."
What Suboxone Film Is and How It Damages Teeth
Suboxone film was introduced in 2010 as a successor to the original Suboxone tablet. The film delivered the same active ingredients in a strip designed to dissolve faster, taste better, and be harder to divert (because the film does not crush easily).
The film became the dominant formulation for medication-assisted treatment. By the time generic alternatives entered the market, millions of patients had been prescribed the brand-name film.
The dental-injury mechanism is straightforward dental science. Tooth enamel begins to demineralize at a salivary pH below roughly 5.5. Suboxone film sits at a pH substantially lower than that. Every dose creates an acidic local environment in the mouth, often held under the tongue or against the inner cheek for 5 to 10 minutes while the film dissolves.
Over years of twice-daily or three-times-daily dosing, the cumulative acid exposure produces a recognizable injury pattern. Plaintiffs' dentists describe widespread decay at multiple sites simultaneously, cervical caries at the gum line, and rapid enamel loss that does not fit the patient's prior dental history or normal aging.
The defendant counter is that opioid use disorder itself causes dental problems through behavioral and physiological factors. Specifically, xerostomia (dry mouth) from chronic opioid use reduces salivary buffering of acids, sweet-craving dietary patterns are common in early recovery, and previously deferred dental care often leaves a baseline of untreated decay. Plaintiffs counter that the Suboxone-specific acidic-pH mechanism is an independent driver of demineralization regardless of those background factors, and that dentists routinely observe rapid widespread decay patterns in Suboxone film patients that do not match opioid-use-disorder dental presentations alone. The American Dental Association has issued patient guidance recommending water rinses after sublingual film dosing and dental monitoring for patients on long-term buprenorphine therapy.
- FDA required a dental-decay warning in June 2022 after reviewing 305 adverse-event reports (federal regulatory acknowledgment of the risk)
- Acidic-pH dental erosion is established science independent of any opioid-use-disorder confound
- Patient population is documented through Suboxone prescription records, making product identification straightforward
- Internal Indivior and Reckitt records on the dental risk are central to discovery
The June 2022 FDA Dental-Decay Warning
The FDA action in June 2022 is the procedural pivot for the litigation. The agency required Indivior to add a new warning to the Suboxone film label disclosing the risk of dental decay, cavities, oral infections, and tooth loss. The FDA Drug Safety Communication identified "cavities and tooth decay, including rampant caries; dental abscesses and infection; tooth erosion; fillings falling out; and, in some cases, total tooth loss" as documented effects, and recommended dental evaluation before starting treatment.
The warning was supported by FDA's review of 305 adverse-event reports filed between 2007 and mid-2021. Twenty-eight of those reports involved patients with no prior history of dental problems. Many described rapid, severe decay developing after the start of Suboxone film use.
The Failure-to-Warn Theory
Hard Truth: Patients prescribed Suboxone film before June 2022 received a label that did not warn of dental injury. The litigation argues that Indivior and Reckitt knew about the dental risk for years (internal complaints, regulatory queries, published case reports) but did not update the label until federal regulators forced the change. Patients who lost teeth before getting the warning are the core of the plaintiff pool.
Generic Suboxone Film and Preemption
Hard Truth: Generic buprenorphine/naloxone films are subject to the PLIVA v. Mensing preemption doctrine, which bars failure-to-warn claims against generic drug manufacturers in most cases. Plaintiffs who took only generic film face a steeper legal path. Plaintiffs who took the brand-name Suboxone film, or who took the brand and later switched to generic, have stronger claims against Indivior under Wyeth v. Levine.
Indivior's Prior Track Record
Hard Truth: Indivior pleaded guilty in 2020 to felony health care fraud related to Suboxone marketing and agreed to pay over $600 million to resolve federal and state claims. The settlement involved allegations that Indivior misrepresented the safety profile of the film versus the tablet. That history is admissible context in the current dental-injury litigation and frames the failure-to-warn theory in a particular light.
Named Defendants: Indivior, Reckitt, and Aquestive
The corporate chain behind Suboxone film matters for liability allocation:
Named Defendants and Corporate Chain
Indivior is the current manufacturer and marketer of brand-name Suboxone film. The company is the principal defendant in MDL 3092. Indivior's 2020 federal plea and $600M+ settlement related to earlier Suboxone marketing conduct is admissible background.
Reckitt Benckiser was the parent company that developed and marketed Suboxone before the 2014 spinoff of Indivior. Reckitt is named in claims tied to conduct during its period of ownership. Pre-2014 prescriptions implicate Reckitt's marketing and label decisions.
Aquestive Therapeutics developed the PharmFilm technology underlying the Suboxone sublingual film formulation. Whether Aquestive remains in the case depends on the specific claims and the contractual relationships with Indivior. The company's role is part of discovery.
Reckitt spun off its pharmaceutical business as Indivior in December 2014. Both entities can be named depending on when the plaintiff was prescribed Suboxone film. Pre-2014 claims target Reckitt; post-2014 claims target Indivior. Long-term users prescribed before and after often name both.
Pharmaceutical Mass Tort Defense Pattern
Indivior and Reckitt will run the standard pharmaceutical mass tort defense playbook: federal preemption arguments, learned-intermediary doctrine, alternative-cause arguments tied to opioid use disorder, and statute-of-limitations challenges.
The June 2022 FDA label change is a double-edged sword for the defendants. It is regulatory acknowledgment of the risk, which helps plaintiffs prove the underlying causation. But it also gives the defendants a discovery date argument: claims accruing well after June 2022 face a tougher discovery-rule analysis because the warning was on the label by then.
HARD TRUTH: The strongest Suboxone tooth decay cases are patients who started brand-name film well before June 2022, who developed substantial dental injury during use, and who have clear dental records bracketing the prescription history. The same failure-to-warn pattern appears across pharmaceutical mass torts including the Ozempic and GLP-1 receptor agonist litigation.
MDL 3092 at a Glance
Key procedural facts every claimant should understand:
- Case caption: In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092
- Court: U.S. District Court for the Northern District of Ohio, Cleveland Division
- Judge: Hon. Philip Calabrese (case has been before more than one judge as the docket developed)
- Centralized: February 2024, by the JPML
- Pending cases: Continuing to grow as new plaintiffs join
- Defendants: Indivior Inc.; Indivior PLC; Reckitt Benckiser; Aquestive Therapeutics (depending on the case)
- Bellwether posture: Selection in progress; trials being prepared
The MDL coordinates pretrial work for cases sharing the same defendants and the same core failure-to-warn theory. Each plaintiff retains an individual claim and an individual settlement value tied to the severity of dental injury and treatment burden.
Who Qualifies to File a Suboxone Tooth Decay Lawsuit
Eligibility turns on prescription history, dental injury, and timely filing.
- Prescription documentation: Pharmacy records, prescriber records, or insurance claims showing Suboxone film (brand name) prescription history of at least six months. Longer use strengthens the case.
- Qualifying dental injury: Severe decay (multiple teeth affected simultaneously), tooth loss, root canals, crowns, dental implants, bridges, dentures, or full-mouth reconstruction performed during or after the Suboxone prescription period.
- Dental records: Records from before, during, and after the prescription period. The contrast between pre-Suboxone dental status and post-Suboxone dental status is the central causation evidence.
- Diagnosis date: Dental injury discovered within the applicable statute-of-limitations window for your state. The discovery rule typically preserves claims for patients who only recently connected the dental problems to Suboxone use.
- Brand vs. generic: Plaintiffs who took brand-name Suboxone film (Indivior) have the strongest claims. Plaintiffs who took only generic buprenorphine/naloxone film face PLIVA v. Mensing preemption hurdles.
If your dental records are incomplete, share what you have. Dentists retain records for years; a Suboxone lawyer can request them through standard medical-record subpoenas.
Compensation Available in Suboxone Tooth Decay Claims
Damages cover both economic and non-economic losses, and where evidence supports it, punitive damages.
Economic damages: dental treatment costs (extractions, root canals, crowns, implants, bridges, dentures, full-mouth reconstruction), future dental care, lost wages during recovery from oral surgery, and out-of-pocket costs not covered by dental insurance. Dental work routinely runs into the tens of thousands of dollars per patient in severe cases.
Non-economic damages: pain and suffering from the dental decay and surgical interventions, emotional distress, loss of enjoyment of life, social and psychological impact of significant tooth loss, and loss of consortium where applicable.
Punitive damages: available where evidence supports a finding that Indivior and Reckitt knew about the dental-injury risk and continued to market Suboxone film without adequate warnings. The 305 adverse-event reports the FDA reviewed for the 2022 label change form the foundation for this argument.
What Suboxone Settlement Values May Look Like
It is too early to project specific Suboxone settlement tiers. Bellwether trials have not yet returned verdicts. Comparable pharmaceutical mass torts have produced individual recoveries that tier by severity of injury and treatment burden.
Cases involving full-mouth reconstruction, multiple implants, and significant ongoing dental work will sit at the higher end of any matrix that emerges. Cases involving more limited treatment will sit lower. The cost of corrective dental care alone is the anchoring economic damage in most cases.
For broader context on how injury claims are valued, see our explanation of what your injury case is worth.
Filing Deadlines and Procedural Issues
The SOL clock typically starts when the plaintiff knew or should have known the dental injury was linked to Suboxone film. For many plaintiffs, that date is the June 2022 FDA warning or the news coverage that followed. Patients diagnosed years earlier whose dentist did not connect the decay to Suboxone may still be within the filing window.
Product-liability statutes of limitations range from 1 year (Louisiana, Tennessee) to 6 years. Some states have statutes of repose. Your home state determines the deadline and the substantive law applied to your case.
PLIVA v. Mensing (2011) preempts failure-to-warn claims against generic drug manufacturers in most contexts because generics must use the same label as the brand. Brand-name Suboxone film claims against Indivior survive under Wyeth v. Levine. If you took only generic buprenorphine/naloxone film, the legal path is more difficult; a free case review evaluates the specifics.
MDL 3092 has a direct-filing order that lets plaintiffs file in the Northern District of Ohio while preserving home-state-law advantages. Direct filing avoids removal complications and locks in MDL status and bellwether eligibility.
Defenses and Hurdles in Suboxone Tooth Decay Cases
Three contested fronts dominate the litigation.
First, alternative causation. Indivior and Reckitt argue that opioid use disorder itself causes dental problems through xerostomia (dry mouth), dietary changes, and deferred dental care. Plaintiffs counter with the dental-science evidence that low-pH film exposure independently demineralizes tooth enamel, and with dental records that show normal pre-Suboxone dental status followed by rapid post-Suboxone decay.
Second, federal preemption. Brand-name Suboxone claims survive under Wyeth v. Levine. Generic claims face PLIVA v. Mensing preemption. Plaintiffs who took both must establish liability against Indivior for the brand-name portion of the prescription history.
Third, statute of limitations and the June 2022 warning. The defense argues that the warning shifted the discovery-rule clock. Plaintiffs argue that the connection between Suboxone and dental injury was not widely understood until the litigation publicized it.
None of these defenses defeat the litigation. They affect timeline and per-case value. The same defense playbook appears across pharmaceutical mass torts including the Ozempic gastroparesis litigation and the hair relaxer cancer cases.
How to File a Suboxone Tooth Decay Lawsuit
The intake process is straightforward when you work with a firm familiar with MDL 3092.
Step one: free case review. Share your Suboxone prescription history, your dental history before and during use, and any treatment you have undergone or need.
Step two: pharmacy and dental records collection. We request Suboxone film prescription records from your pharmacy chain (most retain records for at least 10 years) and dental records from each dentist who treated you.
Step three: filing. Most cases are filed directly in MDL 3092 in N.D. Ohio under the court's direct-filing order.
Step four: plaintiff fact sheet. The MDL requires a detailed fact sheet documenting medical history, prescription timeline, dental injury course, and damages.
Step five: discovery and resolution. Through bellwether outcomes, individual settlement, or remand for trial in your home court.
Contingency fee. No money out of pocket. No fee unless we recover for you.
Time Pressure: Why Sooner Is Better Than Later
Pharmacy chains retain prescription records for limited periods (often 10 years, sometimes less depending on the chain and state regulations). Dentists transition practices and records get archived. The earlier you start, the easier the documentation gathering is.
If you were prescribed Suboxone film and developed severe dental problems, the case review costs nothing and clarifies your filing window under your state's statute of limitations. Waiting can make documentation harder and can close doors that did not need to close.
Suboxone Tooth Decay Lawsuit: Frequently Asked Questions
- Q: Does Suboxone cause tooth decay?
-
A: The FDA required Indivior to add a dental-decay warning to the Suboxone film label in June 2022, after reviewing 305 adverse-event reports. The plaintiffs' theory is that the film's acidic pH demineralizes tooth enamel during repeated dissolution under the tongue. Enamel begins to demineralize below pH 5.5; Suboxone film sits well below that. Indivior contests independent causation, citing opioid use disorder factors. The litigation will resolve the causation question.
- Q: I took brand-name Suboxone film for years and lost teeth. Do I have a case?
-
A: Probably yes. Long-term brand-name Suboxone film use plus documented dental injury (decay, extractions, root canals, implants, crowns) is the core fact pattern in MDL 3092. The strongest cases have clear dental records bracketing the prescription period showing normal teeth before Suboxone and rapid decay during use. A Suboxone tooth decay attorney evaluates the documentation.
- Q: I only took generic Suboxone film. Do I still have a claim?
-
A: Generic claims face PLIVA v. Mensing federal preemption, which bars most failure-to-warn claims against generic drug manufacturers. The legal path for generic-only claimants is harder. If you took brand-name Suboxone at any point in your prescription history, even before switching to generic, your case is stronger because the brand period supports a claim against Indivior. A free case review evaluates the specifics.
- Q: What is the average Suboxone tooth decay settlement?
-
A: A global settlement matrix has not been finalized. Bellwether trials are still being prepared. Comparable pharmaceutical injury cases tier settlement values by severity of injury and treatment burden. Cases involving full-mouth reconstruction, multiple implants, and significant ongoing dental work will sit higher in any matrix that emerges. Cases involving more limited treatment will sit lower.
- Q: How long do I have to file a Suboxone lawsuit?
-
A: State law governs. Product-liability statutes of limitations range from 1 year to 6 years depending on the state. Most states apply the discovery rule, meaning the clock starts when a reasonable person would have linked the dental injury to Suboxone film. The June 2022 FDA warning is a common reference date. A free case review confirms your state's deadline.
- Q: How do I find a Suboxone attorney near me?
-
A: Most cases are filed directly in MDL 3092 in the Northern District of Ohio under the court's direct-filing order, which preserves home-state-law advantages. You do not need an attorney physically located in your home state. You want a Suboxone law firm with MDL experience, the resources to fund a multi-year case, and a documented relationship with the plaintiffs' steering committee. The case review is free.
- Q: What does a Suboxone lawyer cost?
-
A: Contingency fee. No upfront fees, no hourly billing, no out-of-pocket costs. Attorney fees come from money recovered in your case. If we do not recover, you owe nothing.
- Q: Is the Suboxone lawsuit a class action?
-
A: No. MDL 3092 is multidistrict litigation, which is different from a class action. Each plaintiff retains an individual claim with an individual settlement value tied to the severity of dental injury and treatment burden. The MDL coordinates pretrial work (discovery, expert challenges, bellwether trials) for cases that share common questions, but the individual cases remain separate. Many lay searchers call it a class action; the formal label is mass tort or MDL.
- Q: I take Subutex, Zubsolv, or Sublocade, not Suboxone. Can I still file?
-
A: The MDL 3092 litigation focuses specifically on Suboxone sublingual film (Indivior). Subutex (buprenorphine-only sublingual tablet) and Zubsolv and Bunavail (other branded buprenorphine/naloxone formulations from different manufacturers) involve different products with different pH profiles, dissolution times, and marketing histories. The legal path for those other products is separate and may face different preemption and causation hurdles. Sublocade, the long-acting subcutaneous injectable, has minimal oral contact and is generally not part of the dental-injury claims. A free case review evaluates the specifics of your prescription history.
- Q: When will Suboxone settlement checks be paid out?
-
A: Too early to say. No global settlement framework has been finalized. Mass-tort settlement programs typically take 18 to 36 months from announcement to claim-payment after bellwether trials produce verdicts that anchor negotiations. The Suboxone tooth decay MDL is still in discovery and bellwether preparation. Once a settlement framework is announced, the claims-administration timeline involves submitting documentation, tier assignment, and disbursement. Patience is part of the process; the timeline is largely outside individual plaintiff control.
Talk to a Suboxone Tooth Decay Lawyer Today
If you were prescribed Suboxone sublingual film and developed severe tooth decay, tooth loss, oral infections, or required substantial dental treatment during or after use, you may qualify to file a claim in MDL 3092.
The case review is free and confidential. We handle Suboxone tooth decay cases on contingency. You owe nothing unless we recover compensation for you.
Free Case Evaluation
FILL OUT THE FORM BELOW
TO REQUEST YOUR CASE REVIEW
External Resources
Legal Representation
"Speak with our pharmaceutical injury attorneys for a free, confidential review of your potential Suboxone tooth decay claim. Past results vary based on the unique facts of each case."
Find out more >>